Zydus Cadila gets USFDA nod for kidney stones tablets

Tags: Companies
Drug firm Zydus Cadila has received the final approval from the US health regulator to market Potassium Citrate ER tablets used in prevention of kidney stones.

Zydus Cadila has received the final approval from the United States Food and Drug Administration (USFDA) to market Potassium Citrate ER tablets in the strengths of 5 mEq, 10 mEq and 15 mEq, said the Zydus group's listed entity, Cadila Healthcare, said in a statement.

"The estimated sales in 2014 for Potassium Citrate ER tablets is $131.7 million, as per IMS," it added.

The group currently has 94 approvals and has so far filed 239 abbreviated new drug applications (ANDA), Cadila Healthcare said.

Shares of Cadila Healthcare were trading at Rs 1,098.95 per scrip in the afternoon trade on the BSE, up 0.35% from the previous close.

EDITORIAL OF THE DAY

  • India’s commercial links with Britain since Company Raj will still prosper

    There is little point in shedding tears over Britain’s exit from the European Union (EU).

FC NEWSLETTER

Stay informed on our latest news!

TODAY'S COLUMNS

Amita Sharma

Regimenting art runs counter to a creative society

For poetry makes nothing happen,” so said American poet WH ...

Zehra Naqvi

Of traitors & cadavers

There’s nothing like a book that arrests you from the ...

Dharmendra Khandal

Why drone technology doesn't work

Poaching and anti-forestry activities are a problem for forest departments ...